The biology underlying molecular imaging in oncology: from genome to anatome and back again

Clinical Radiology

Volumn 65, Issue 7, 2010, Pages 517-521

  Gillies, R J ^a   Anderson, A R ^a   Gatenby, R A ^a   Morse, D L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR;

ANATOME; COMPUTATIONAL FLUID DYNAMICS; DIFFUSION TENSOR IMAGING; DYNAMICS; ECOSYSTEM; ENVIRONMENT; GENE EXPRESSION; GENOME; HEREDITY; METABOLOME; MOLECULAR BIOLOGY; MOLECULAR IMAGING; ONCOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENOME; HUMANS; MODELS, BIOLOGICAL; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NEOPLASMS; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 77953305247     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2010.04.005     Document Type: Review

References (57)

1. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nature Rev 10 (2009) 704-714
2. Hager G.L., McNally J.G., and Misteli T. Transcription dynamics. Mol Cell 35 (2009) 741-753
3. Munshi A., Shafi G., Aliya N., et al. Histone modifications dictate specific biological readouts. J Genet Genomics 36 (2009) 75-88
4. Cairns B.R. The logic of chromatin architecture and remodelling at promoters. Nature 461 (2009) 193-198
5. Zheng Y.G., Wu J., Chen Z., et al. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev 28 (2008) 645-687
6. Carninci P., Yasuda J., and Hayashizaki Y. Multifaceted mammalian transcriptome. Curr Opin Cell Biol 20 (2008) 274-280
7. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nature Rev 8 (2007) 829-833
8. Ponder B.A. Cancer genetics. Nature 411 (2001) 336-341
9. Anderson A.R., Rejniak K.A., Gerlee P., et al. Microenvironment driven invasion: a multiscale multimodel investigation. J Math Biology 58 (2009) 579-624
10. Gatenby R.A., and Vincent T.L. Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther 2 (2003) 919-927
11. Anderson A.R., Weaver A.M., Cummings P.T., et al. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127 (2006) 905-915
12. Gerlee P., and Anderson A.R. Modelling evolutionary cell behaviour using neural networks: application to tumour growth. Biosystems 95 (2009) 166-174
13. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12 (1992) 5447-5454
14. Semenza G.L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19 (2009) 12-16
15. 2 sensing and cancer. Nat Rev Cancer 8 (2008) 865-873
16. Gillies R.J., Robey I., and Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 Suppl. 2 (2008) 24S-42S
17. Gillies R.J., Schornack P.A., Secomb T.W., et al. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1 (1999) 197-207
18. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
19. Kroemer G., and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13 (2008) 472-482
20. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
21. Gatenby R.A., and Gillies R.J. A microenvironmental model of carcinogenesis. Nat Rev Cancer 8 (2008) 56-61
22. Jordan B.F., Runquist M., Raghunand N., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7 (2005) 475-485
23. Stephen R.M., and Gillies R.J. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 24 (2007) 1172-1185
24. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
25. Taylor J.S., Tofts P.S., Port R., et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10 (1999) 903-907
26. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 (2005) 1599-1610
27. Jackson A., O'Connor J.P., Parker G.J., et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13 (2007) 3449-3459
28. Buonaccorsi G.A., O'Connor J.P., Caunce A., et al. Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data. Magn Reson Med 58 (2007) 1010-1019
29. Issa B., Buckley D.L., and Turnbull L.W. Heterogeneity analysis of Gd-DTPA uptake: improvement in breast lesion differentiation. J Comp Assist Tomogr 23 (1999) 615-621
30. Rose C.J., Mills S.J., O'Connor J.P., et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 62 (2009) 488-499
31. Prescott J.W., Zhang D., Wang J.Z., et al. Temporal analysis of tumor heterogeneity and volume for cervical cancer treatment outcome prediction: preliminary evaluation. J Digit Imaging 23 (2010) 342-357 [Epub 2009 Jan 27]
32. Som P., Atkins H.L., Bandoypadhyay D., et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21 (1980) 670-675
33. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002) 683-693
34. Zhao S., Kuge Y., Mochizuki T., et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46 (2005) 675-682
35. Eary J.F., O'Sullivan F., O'Sullivan J., et al. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J Nucl Med 49 (2008) 1973-1979
36. O'Sullivan F., Roy S., O'Sullivan J., et al. Incorporation of tumor shape into an assessment of spatial heterogeneity for human sarcomas imaged with FDG-PET. Biostatistics 6 (2005) 293-301
37. Kidd E.A., and Grigsby P.W. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 14 (2008) 5236-5241
38. Petit S.F., Aerts H.J., van Loon J.G., et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother Oncol 91 (2009) 393-398
39. Hamstra D.A., Rehemtulla A., and Ross B.D. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25 (2007) 4104-4109
40. Chenevert T.L., Meyer C.R., Moffat B.A., et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1 (2002) 336-343
41. Evelhoch J.L., Gillies R.J., Karczmar G.S., et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2 (2000) 152-165
42. Bennett K.M., Hyde J.S., and Schmainda K.M. Water diffusion heterogeneity index in the human brain is insensitive to the orientation of applied magnetic field gradients. Magn Reson Med 56 (2006) 235-239
43. Kwee T.C., Galban C.J., Tsien C., et al. Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas. NMR Biomed 23 (2010) 179-187
44. Le Bihan D., Poupon C., Amadon A., et al. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging 24 (2006) 478-488
45. Hobbs S.K., Shi G., Homer R., et al. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 18 (2003) 530-536
46. Van Meter T., Dumur C., Hafez N., et al. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15 (2006) 195-205
47. Tebbit C.L., Zhai J., Untch B.R., et al. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat 118 (2009) 635-643
48. Lee T.Y., Purdie T.G., and Stewart E. CT imaging of angiogenesis. Q J Nucl Med 47 (2003) 171-187
49. Mut M., Turba U.C., Botella A.C., et al. Neuroimaging characteristics in subgroup of GBMs with p53 overexpression. J Neuroimaging 17 (2007) 168-174
50. Sullivan D.C. Challenges and opportunities for in vivo imaging in oncology. Technol Cancer Res Treat 1 (2002) 419-422
51. Giger M.L., Chan H.P., and Boone J. Anniversary paper. History and status of CAD and quantitative image analysis: the role of Medical Physics and AAPM. Med Phys 35 (2008) 5799-5820
52. Yuan Y., Giger M.L., Li H., et al. Correlative feature analysis on FFDM. Med Phys 35 (2008) 5490-5500
53. Li H., Giger M.L., Yuan Y., et al. Evaluation of computer-aided diagnosis on a large clinical full-field digital mammographic dataset. Acad Radiol 15 (2008) 1437-1445
54. Diehn M, Nardini C, Wang DS, et-al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105:5213-5218.
55. Segal E., Sirlin C.B., Ooi C., et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nature Biotechnol 25 (2007) 675-680
56. Henson J.W., Gaviani P., and Gonzalez R.G. MRI in treatment of adult gliomas. Lancet Oncol 6 (2005) 167-175
57. Rees J.H., Smirniotopoulos J.G., Jones R.V., et al. Glioblastoma multiforme: radiologic-pathologic correlation. RadioGraphics 16 (1996) 1413-1438 quiz 62-63